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tespite significant progress in the prevention and treatment
f cardiovascular diseases over the past 2 decades, the
ncidence, prevalence, morbidity, mortality, and economic
mpact associated with heart failure (HF) represent a major
nd growing public health concern (1,2). Thrombotic oc-
lusions and thromboembolism are critical, but relatively
ncommon life-threatening complications of HF. The ex-
stence of HF per se increases the risk of thromboembolic
vents, regardless of whether concomitant atrial fibrillation
s present (3,4). Clopidogrel is a second-generation thien-
pyridine, an adenosine diphosphate receptor antagonist
cting via platelet P2Y12 receptor blockade, and an estab-
ished antiplatelet agent. Clopidogrel either as an alternative
5), or more commonly as an adjunct (6), to aspirin
epresents a cornerstone of modern chronic oral antiplatelet
See page 1300
herapy for treatment and secondary prevention of acute
ascular events. However, the role of antithrombotic ther-
py in general, and clopidogrel in particular, in patients with
F has long been debated. Several markers of platelet
ctivity subsequently have been found to be increased in HF
atients, including thromboglobulin, platelet factor 4, and
ellular adhesion molecules such as P-selectin, platelet and
ndothelial cell adhesion molecule, and osteonectin (7–9).
he pathogenesis of platelet activation in HF remains to be
stablished; it is probably multifactorial and related to
alcium imbalance, sympathoadrenal activation, catechol-
mine release, and reduced kidney and liver blood flow,
esulting in decreased clearance of platelet-activating sub-
tances. Nevertheless, therapy with clopidogrel inhibited
latelet indexes independently of HF cause, New York
eart Association functional class, or ejection fraction
10,11).
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iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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hanges in platelet indexes after clopidogrel in patients with
F: positive results of randomized trials with clopidogrel in a
eripheral vascular disease cohort (6), stroke (12), and coronary
rtery disease (6,7,13,14), but negative data from the long-
waited—although underpowered because of low enroll-
ent—WATCH (Warfarin and Antiplatelet Therapy in
hronic Heart Failure) trial (15). It is still unclear whether
lopidogrel use is justified for all HF patients, whether it
hould be limited only to patients with HF of ischemic origin,
r whether bleeding risks outweigh vascular benefits, challeng-
ng any use of clopidogrel in the HF population. Because the
ata on these critical issues are very limited, the elegant and
onvincing report published in this issue of the Journal (16) is
f unquestionable practical importance. Using the National
atient Register of 56,994 first documented myocardial infarc-
ions (MIs) in Denmark, Bonde et al. (16) demonstrated
ighly significant positive impact of clopidogrel use on mor-
ality reduction in patients with antecedent HF (hazard ratio:
.86; 95% confidence interval: 0.78 to 0.95; with a highly
ignificant p  0.002) compared with patients with HF, but
ot treated with clopidogrel. Importantly, such an impressive
utcome benefit occurs over a relatively short follow-up,
uggesting potentially even better long-term survival. Impact
nmortality in theDanishMI cohort is impressive, the hardest
o achieve, and unquestionably the most important outcome
easure yielded from the National Prescription Registry,
specially considering that the data were pooled from the entire
opulation of Denmark. Notably, the diagnosis codes of MI
reviously were validated with a sensitivity of 91% and a
ositive predictive value of 93% (17), improving the quality of
he current analyses even further. Importantly, oral antiplatelet
gents belong to the elite class of pharmaceuticals known to
educe mortality significantly in outcome-driven clinical stud-
es. Historically, only 2 clinical trials, one with aspirin (18) and
he other with clopidogrel (14), were associated with rare
bsolute mortality reduction benefit in patients after acute
ascular thrombotic events. Recently, a remarkable and some-
hat surprising achievement has been reported with ticagrelor
n the PLATO (PLATelet Inhibition and Clinical Outcomes)
rial (19), when 107 more lives were saved with ticagrelor than
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March 30, 2010:1308–9 Clopidogrel and HF Survivalbsolute mortality reduction (hazard ratio: 0.78; 95% confi-
ence interval: 0.69 to 0.89; p  0.001). However, being a
rst-in-class cyclopentyl-triazolo-pyrimidine, ticagrelor is not a
ure antiplatelet agent and exhibits numerous properties be-
ond platelet inhibition via modulation of plasma adenosine
evels and up-regulation of adenosine receptors (20). Recog-
izing the mortality advantage of aspirin in ISIS-2 (Second
nternational Study of Infarct Survival) (18), clopidogrel in
OMMIT (Clopidogrel and Metoprolol in Myocardial In-
arction Trial) (14), and ticagrelor in PLATO (19), the
ositive impact of clopidogrel on HF survival may be antici-
ated and is not that surprising. A few issues, however, remain
nsettled. The registry does not collect many clinical charac-
eristics such as blood pressure, left ventricular ejection fraction,
-type natriuretic peptide levels, and other risk factors that
ould define how the HF origin, severity, comorbidities, or
oncomitant medications influenced the patients’ prognosis.
lso, the study was not controlled for clopidogrel compliance,
uration of antiplatelet therapy, drug intolerance, or, finally,
ide effects, including bleeding complications.
Aside from the failure of the WATCH trial to show
uperiority of clopidogrel over aspirin, and especially over
arfarin (15), we have no randomized evidence linking
lopidogrel, HF, and improved survival. The highly antic-
pated results of the WARCEF (Warfarin versus Aspirin in
atients with Reduced Cardiac Ejection Fraction) trial (21)
re pending, although the clopidogrel arm is lacking in that
tudy. A head-to-head randomized study of conventional HF
herapy with and without clopidogrel is needed urgently,
lthough the chances for such a study are slim considering
eneric clopidogrel competition, the need for a large sample
ize, and the long 3 to 5 years of follow-up needed to
dequately test the mortality end point hypothesis.
Despite some well-recognized limitations, Bonde et al. (16)
dvanced our current understanding of the potential benefit of
lopidogrel in reducing all-cause mortality in patients after first
I and associated HF. Future attempts to improve survival in
F by reducing platelet activation and thrombotic burden are
arranted. Reduced-dose, once-daily ticagrelor looks especially
romising considering the remarkable absolute mortality ben-
fit achieved in the recent PLATO trial.
eprint requests and correspondence: Dr. Victor L. Serebruany,
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